|Dr. Steve N. Slilaty||Chairman, CEO & Pres||28k||N/A||1952|
|Mr. Camille Sebaaly||CFO, Sec. & Director||25k||N/A||1959|
|Dr. Abderrazzak Merzouki||COO & Director||19.92k||N/A||1964|
|Mr. Robert G. Ferreira||Pres of Sunshine Bio Investments Inc||N/A||N/A||1962|
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on development of anticancer drug. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells. It also provides generic prescription drugs for the treatment of breast cancer, prostate cancer, and benign prostatic hyperplasia; chemical analysis of pharmaceutical and other industrial samples; and Essential 9, a dietary supplement. Sunshine Biopharma, Inc. has an agreement with the University of Georgia to advance the development of Sunshine Biopharma's announced anti-Coronavirus lead compound, SBFM-PL4. The company is based in Pointe-Claire, Canada.
Sunshine Biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.